title: [Neovascular glaucoma treatment in 2012: role of anti-VEGF agents].
abstract: Neovascular glaucoma is a serious pathology with a variety of causes. It results from the secretion by hypoxic retinal tissue of growth factors, including vascular endothelial growth factor (VEGF). Anterior segment involvement begins in the iris, followed by the development of a fibrovascular membrane in the angle, with resultant goniosynechiae. Treatment of the underlying disease consists most often of panretinal photocoagulation. As for the secondary sequelae, current treatment consists of intravitreal injection of anti-VEGF agents. The most utilized agent is bevacizumab or Avastin, off-label. Avastin is effective against neovascularization and ocular hypertension, especially in the early stages. It also represents an adjunct to filtering surgery. It appears to be very well tolerated.
authors.affiliation: Service d'ophtalmologie, université de Lyon I Claude-Bernard, hôpital de Croix-Rousse, 103, grande rue de Croix-Rousse, 69004 Lyon, France. kodjikian.laurent@wanadoo.fr
authors.forename: L
authors.initials: L
authors.lastname: Kodjikian
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D015355:Glaucoma, Neovascular / Q000188:drug therapy / Q000209:etiology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008954:Models, Biological; D009885:Ophthalmology / Q000379:methods / Q000639:trends*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000276:immunology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab